TY - JOUR
T1 - The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares
T2 - Induction of ovulation, hormone profiles, and inter-ovulatory intervals
AU - Yoon, M. J.
AU - Boime, I.
AU - Colgin, M.
AU - Niswender, K. D.
AU - King, S. S.
AU - Alvarenga, M.
AU - Jablonka-Shariff, A.
AU - Pearl, C. A.
AU - Roser, J. F.
PY - 2007/11
Y1 - 2007/11
N2 - The objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3-20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12 h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12 h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17β (E2), and progesterone (P4) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0 mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.
AB - The objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3-20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12 h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12 h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17β (E2), and progesterone (P4) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0 mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.
KW - Equine
KW - In vivo
KW - LH
KW - Mare
KW - Recombinant single chain
UR - http://www.scopus.com/inward/record.url?scp=34848831115&partnerID=8YFLogxK
U2 - 10.1016/j.domaniend.2007.06.001
DO - 10.1016/j.domaniend.2007.06.001
M3 - Article
C2 - 17658237
AN - SCOPUS:34848831115
SN - 0739-7240
VL - 33
SP - 470
EP - 479
JO - Domestic Animal Endocrinology
JF - Domestic Animal Endocrinology
IS - 4
ER -